Last reviewed · How we verify
Comp01
The mechanism of action for Comp01 is currently under investigation and not fully characterized.
At a glance
| Generic name | Comp01 |
|---|---|
| Sponsor | Promius Pharma, LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
Comp01 is in phase 2 clinical trials, and its precise mechanism of action has not been fully elucidated. Further research is needed to determine how it interacts with biological systems.
Approved indications
Common side effects
Key clinical trials
- A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis (PHASE3)
- DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis (PHASE2)
- ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comp01 CI brief — competitive landscape report
- Comp01 updates RSS · CI watch RSS
- Promius Pharma, LLC portfolio CI